Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A synthetic heptapeptide analog of tuftsin developed by the Institute of Molecular Genetics in Russia. Approved in Russia as an anxiolytic and nootropic. Widely used for anxiety reduction and cognitive enhancement without sedation.
A synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation and Gerontology — the same institution behind Epitalon. Pinealon is designed to target the central nervous system and pineal gland, with research focused on neuroprotection, cognitive function, and circadian rhythm regulation.
Modulates GABA-A receptor activity and increases BDNF expression. Stabilizes enkephalins (endogenous opioid peptides) by inhibiting their enzymatic breakdown, prolonging their anxiolytic effects. Also modulates serotonin, dopamine, and norepinephrine systems.
Penetrates the blood-brain barrier and accumulates in neurons. Modulates gene expression related to neuronal survival and function. Reduces oxidative stress in neural tissue. Appears to regulate melatonin synthesis through pineal gland activity, supporting circadian rhythm normalization.
- Anxiety and stress reduction
- Cognitive enhancement and focus
- Depression support
- Immune system modulation
- Memory improvement
- Cognitive enhancement and memory
- Neuroprotection
- Sleep quality improvement
- Age-related cognitive decline
- Stroke recovery support (preliminary research)
- Limited Western clinical trial data
- Nasal spray may cause mild irritation
- Potential fatigue at higher doses
- Long-term safety profile not established in Western populations
- Interactions with other anxiolytics not well characterized
- Very limited independent Western research
- Most studies from Russian institutions
- Long-term safety unknown
- Mechanism not fully characterized
- Injection site reactions
Not FDA-approved and not currently on any FDA compounding list. Available as a research chemical. Approved in Russia as an anxiolytic drug. Not affected by the April 2026 Category 2 removal action.
Not FDA-approved and not on any compounding list. Available as a research chemical. Research base is almost entirely from Russian institutions — independent replication is limited. Not affected by the 2026 regulatory changes.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.